Merger & Acquisition Trends in Pharma – Q1 2026
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report analyzes the merger and acquisition (M&A) activity in Q1 2026 in the Pharma sector.
Scope
This report provides an overview of M&A activity globally in Q1 2026 in the Pharma sector involving biopharmaceutical drug companies.
It identifies key trends, and the most notable deals announced in Q1 2026 in the Pharma sector.
Key Highlights
In Q1 2026, the global pharma sector recorded a drop in deal value to $55.4 billion, down 31.5% from Q4 2025. Deal volume edged up 0.9% to 108 M&A transactions. Oncology emerged as the leading therapeutic area recording 43 deals.
Reasons to Buy
Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Arcellx
Eli Lilly
Centessa Pharmaceuticals
Terns Pharmaceuticals
Merck
Biogen
Apellis Pharmaceuticals
Novartis
Pikavation Therapeutics
Les Laboratoires Servier
Day One Biopharmaceuticals
Orna Therapeutics
Ouro Medicines
RAPT Therapeutics
Excellergy
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports